RYTM Rhythm Pharmaceuticals, Inc.
$119.04
Rhythm Pharmaceuticals, Inc. (RYTM) Earnings News
Earnings press releases, previews and reviews for Rhythm Pharmaceuticals, Inc. (RYTM), newest first. Our most recent is review: Rhythm Pharmaceuticals Beats as Hypothalamic Obesity Launch Accelerates, but New Debt and LG Chem Payments Recast the Story.
Wednesday
November 4, 2026
8:00 AM ET
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome
Tuesday
November 3, 2026
10:45 AM ET
Rhythm Pharmaceuticals Beats as Hypothalamic Obesity Launch Accelerates, but New Debt and LG Chem Payments Recast the Story
Earnings Whispers · Review
Tuesday
November 3, 2026
7:00 AM ET
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update
Monday
October 26, 2026
6:04 PM ET
Rhythm's Incivri Launch Faces Its First Real Test as Street Bets on 18% Sequential Jump
Earnings Whispers · Preview
Wednesday
October 21, 2026
8:00 AM ET
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Tuesday
August 4, 2026
7:01 AM ET
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Tuesday
July 21, 2026
8:00 AM ET
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Friday
June 12, 2026
4:01 PM ET
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome